Drug intelligence / Profile preview

26ND03

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

26ND03 is a small molecule drug candidate currently in the discovery stage of development by HK inno.N (formerly CJ Healthcare). It is being investigated for the treatment of sarcopenia, a condition characterized by the progressive and generalized loss of skeletal muscle mass and strength, often associated with aging. As of early 2026, the specific biological target and mechanism of action for 26ND03 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on 26ND03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26ND03.

Explore the full profile